Clinical Trial

Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial

Study acronym: RELEVANT-HCC
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of regorafenib as a subsequent therapy for patients with hepatocellular carcinoma (HCC) who have failed prior lenvatinib treatment. This investigational study aims to assess the therapeutic benefits and safety profile of regorafenib in patients whose disease has progressed following the use of lenvatinib, a targeted therapy for hepatocellular carcinoma
Trial Details
NCT Number NCT07514429
Lead Sponsor Ju Hyun Shim
Collaborators: Boryung Pharmaceutical Co., Ltd, Samsung Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital, National Cancer Center, Korea, Hanyang University Guri Hospital
Conditions Carcinoma, Hepatocellular, Lenvatinib, Treatment Failure
Enrollment 24 participants
Start Date 2026-03-15
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-07